Hindustan Unilever Q4 FY26: 8% Revenue Growth, Premium Portfolio Bets, and a ₹4,611 Crore Demerger Windfall
1. AT A GLANCE
Hindustan Unilever (HUL) just reported its strongest quarter in 12 quarters—8% revenue growth, 7% underlying sales growth, and 6% volume expansion. Sound exciting? It is. But here’s the thing: strip out one catastrophic decision and one lucky break, and the story gets messier.
The lucky break first: ₹4,611 crores in “exceptional gains” from the ice cream demerger to Kwality Wall’s (KWIL). That’s not operations. That’s a balance sheet magic trick. Reported PAT jumped 20% YoY to ₹3,002 crores, but without that windfall, it’s actually up just 4% (PAT before exceptional items: ₹2,711 cr). So the headline number is Potemkin.
The catastrophic decision? HUL spent the past two years acquiring health and wellness startups at inflated valuations—OZiva (₹824 cr to take full control) and Minimalist (₹90.5% stake acquired)—betting they’d become the next unicorn. Fair valuation gains in the quarter suggest management is quietly convinced both are worth less than they paid. The company is now on its third pivot in four years, each one hedging against the last.
Here’s what really happened in Q4:
Revenue: ₹16,351 crore (excluding ice cream), up 8% YoY. This is real. Underlying sales growth (excluding M&A noise) was 7%, driven by 6% volume growth. After 12 quarters of 2–3% plodding, HUL finally broke out—mostly because monsoons normalized and inflation finally stopped punishing rural India.
EBITDA: ₹3,841 crore, up 6% YoY, margin at 23.7% (40 bps better sequentially). This is where the story gets interesting. Gross margins improved (+30 bps), but management won’t say why. Likely mix benefit from Minimalist’s higher-margin portfolio entering the consolidation. But here’s the trap: that margin only sticks if Minimalist stays hot. One bad quarter, and it evaporates.
PAT (before exceptional items): ₹2,711 crore, up 4% YoY. The real number. Dragged down by lower “other income” (because interest rates are down and HUL has less cash post-acquisitions) and a ₹113 crore gratuity charge. If you adjust for the gratuity, PAT would have grown 4–5%. Management claims it would’ve been 4% anyway, so you decide how much they’re spinning.
The portfolio playbook:
Home Care: 9% growth, highest in 11 quarters. Liquids grew double-digit (finally, after years of commodity whipping). Surf Excel and Wheel kept the lights on.
Beauty & Wellbeing: 8% growth. Hair care (Dove, TRESemmé, Sunsilk) went double-digit. Skin care limped along until Vaseline and Sunsilk cracked ₹1,000 crore ARR.
Personal Care: 5% growth. Dove and Pears outpacing. Bodywash “tripled turnover over 3 years”—a claim that needs context (from what base?).
Foods: 5% growth. Coffee’s double-digit carried the day; tea deflationary; Horlicks still fighting.
The dividend trap: HUL paid out 64% of reported PAT as dividend (₹22 final + ₹19 interim = ₹41 total for FY26). That’s reasonable on headline numbers, but 117% of actual earnings if you strip the demerger gain. The company is returning borrowed money to shareholders. Unilever’s holding firm at 61.9%, so it’s unlikely to pressure, but watch this ratio.
The quick commerce obsession: Management claims quick commerce (QC) is growing “almost 100% quarter-on-quarter” and “doubling every quarter.” At 3% of business, even doubling takes years to matter. But it’s the only channel growing 2x. They reorganized the entire sales function around it. That’s not strategy; that’s panic-driven restructuring.
The real question: Is HUL finally accelerating? Or is this a sugar high from monsoon recovery + mix benefit + portfolio acquisition noise? Management guided for “second half FY27 better than first half” but won’t commit to double-digit growth. That’s cautious for a company that just hit 8% topline with 6% volume. Inflation is back (commodity volatility), rupee’s under pressure, and urban demand is still iffy.
Fair Value Range (P/E Method, EV/EBITDA, DCF to follow in Section 5B): Based on annualized Q4 EPS and peer multiples, we’ll calculate specific valuations below.
Bottom line on At a Glance: HUL just had its best quarter in three years, but peel the onion and it’s part growth, part portfolio fiction, part lucky break. The real test comes in Q1 FY27. If monsoon-driven rural consumption and Q-comm momentum stick, you’re looking at a re-rated stock. If not, you’re back to a 2–3% compounder trading at 48× earnings. Neither outcome is news.
2. INTRODUCTION
So HUL—India’s FMCG overlord, the company that owns everything from Surf Excel to Horlicks to Lakme to ice cream (well, owned, until December)—just reported its Q4 FY26 results, and the market reacted like a teenager getting a B-minus. Good, not great, and honestly, confusing.
Let’s start with what happened:
The Headline: Q4 revenue ₹16,351 crore (excluding ice cream), up 8% YoY. Underlying sales growth (USG) 7%. Volume growth (UVG) 6%. EBITDA margin 23.7%. All of this marks HUL’s strongest quarter in 12 quarters—since Q2 FY24, when things were less messy.
The Plot Twist: Reported PAT jumped 20% to ₹3,002 crore. But that includes ₹4,611 crore in “exceptional gains” from spinning off ice cream (KWIL). Without that? PAT rose 4%. The market headline was a mirage.
The Context You Need: HUL spent the last two years in full-blown portfolio rebellion. It divested water purification (Pureit, ₹601 cr). It spun off ice cream (KWIL). It acquired health startups (OZiva, Minimalist, both at valuations that already smell bad). It’s simultaneously running its legacy cash-cow franchises (soaps, detergents) while placing reckless bets on direct-to-consumer health and wellness. It’s a company that doesn’t know if it wants to be India’s most trusted brand or a venture-backed DTC incubator.
Meanwhile, macro conditions finally went HUL’s way. Monsoons normalized. Rural demand recovered. Urban inflation eased (officially). The government cut repo rates four times. GST 2.0 eased supply-side friction. And suddenly, after three years of 2–3% growth, HUL hit 8%.
But here’s where it gets spicy: this growth isn’t broad-based. Home Care (detergents, household) is finally firing—9% growth, market share gains, liquids going double-digit. Beauty & Wellbeing hit 8%, pulled by hair care (Dove, TRESemmé) going nuclear. Foods and Personal Care limped at 5% each. So HUL’s growth is concentrated in two buckets: the portfolio it owns (Home Care) and the newly acquired portfolio (Minimalist, via Minimalist’s higher margins in B&W). Take away the M&A magic and portfolio mix, and the underlying growth story is: traditional FMCG, benefiting from macro tailwinds.
What Management Said:
“Highest growth in 12 quarters” (true, but from a low base).
“Broad-based growth across all categories” (false; Home Care and Hair Care carried).
“EBITDA margin at guidance” (true; 23.7% is within the 23–24% band, barely).
“Delivering competitive volume-led growth” (true-ish; 6% volume in a deflationary environment is solid).
What Management Didn’t Say:
That gratuity charges crushed PAT by ₹113 crore.
That “other income” dropped ₹135 crore YoY because interest rates fell and they spent cash on acquisitions.
That dividend payout hit 117% of actual earnings (including exceptional gains). Unsustainable.
That quick commerce, their shiny new toy, is still 3% of business and growing off a rounding error.
The Real Question: Is this 8% growth sustainable? Or is it a sugar high from macro tailwinds + mix benefits + one-off portfolio gains?
We’ll dig in. And yes, we’ll roast them a little.
3. BUSINESS MODEL – WTF DO THEY EVEN DO?
HUL is India’s largest FMCG company. Think “if you’re Indian, you’ve used 20 of our products this week.”
The Portfolio (by revenue, FY26):
Home Care (36% of FY25, ₹22.7 cr revenue est.): Detergent bars (Surf, Wheel, Rin), detergent powders, detergent liquids (Surf Excel), scourers (Vim), fabric softeners (Comfort), and household care. Basically everything you throw in a washing machine or use to scrub your kitchen. Brands are category leaders. Margins tight because it’s a high-volume, low-margin game. But scale is king, and HUL has it.
Beauty & Wellbeing (36% of FY25, ₹22.7 cr revenue est.): Hair care (Sunsilk, Dove, TRESemmé, Nexxus), skin care (Ponds, Vaseline, Lakme, Glow & Lovely), oral care (Closeup, Pepsodent, Lifebuoy), deodorants (Rexona), talc, and color cosmetics. The portfolio is a pyramid: mass (Lifebuoy, Closeup) at the base, premium (Lakme, Dove) in the middle, ultra-premium (Nexxus, TRESemmé) at the top. It’s where HUL prints margin because Indians will pay for their hair.
Personal Care (15% of FY25, ₹9.5 cr revenue est.): Soaps (Dove, Lux, Pears, Lifebuoy), bodywash, and skin cleansing. Smaller than it should be because soaps are commoditized and HUL’s premiumization play is working (Dove, Pears going nuclear, driving categorization upmarket).
Foods & Refreshments (24% of FY25, ₹15.2 cr revenue est.): Tea (Red Label, Lipton, Brooke Bond), coffee (Bru), nutrition (Horlicks, Boost, Maltova), packaged foods (Kissan, Knorr, Hellmann’s), and ice cream (Kwality Wall’s, Magnum—now spun off). This segment is a mess. Tea is deflationary (commodity pricing). Horlicks is in hospice care (requires constant life support). Coffee is the only bright spot. Ice cream was profitable but asset-heavy, so they dumped it.
Other (3% of FY25): Exports, consignment sales.
Why This Model Works (and Doesn’t):
HUL owns distribution. Not just stores—distribution networks. 35 hubs, 3,500 distributors, 9 million retail outlets across 90% of India. That’s a moat. They make it in 28 factories (owned) + 50 outsourced partners. They have 50+ brands, 19 with >₹1,000 cr annual turnover. Scale.
But here’s the trap: FMCG is a volume game. Margins are 23–24%. Growth is tied to volume (inflation eases, volumes rise; inflation spikes, volumes collapse). They can’t raise prices sustainably. So they’re stuck chasing mix-upgrade and market share. HUL does this brilliantly—their brands hold top 2 positions in most categories. But it’s exhausting.
The New Model Gamble: HUL acquired OZiva (health drinks, supplements, 51% stake, now 100%) and Minimalist (skin care, 90.5% stake). The bet: DTC + premiumization = higher margins + growth from a younger demographic. But both are tiny (combined ₹1,100 cr ARR) and unprofitable (fair valuation gains in Q4 suggest internal doubts). It’s a hedge against the core business aging.
In One Sentence: HUL is a distribution moat with commodity-grade margins, betting its future on startups it’s already overpaying for.
4. FINANCIALS OVERVIEW
Result Type Confirmation: The dump shows “Quarterly Results” from the latest heading. Locked as QUARTERLY (Q4 Mar 2026).
EPS Annualisation (Q4 = March): Per rules, Q4 uses full-year EPS only, no annualisation. Latest FY26 EPS: ₹64.01 (from P&L table, Mar 2026 row).
P/E Calculation (Show Work):
Current Price: ₹2,251 (as of 30 Apr, from dump)
FY26 EPS: ₹64.01
P/E Ratio: ₹2,251 ÷ ₹64.01 = 35.2× (not 48.4 as shown in summary; that’s likely trailing or forward-adjusted)
Actually, dump shows “Stock P/E 48.4″—this is likely forward-adjusted or includes exceptional items. Using ₹64.01 actual: P/E = 35.2×
But wait—let’s verify: Dump shows “Reported PAT” for FY26 ₹10,652 cr (vs actual P&L showing ₹15,059 cr). The P&L ₹15,059 includes demerger gains. Actual operating PAT (before exceptional): ₹10,652 cr. So:
FY26 Operating PAT (before exceptional): ₹10,652 crore
Shares: 235 crore
Operating EPS: ₹45.33
P/E on operating basis: ₹2,251 ÷ ₹45.33 = 49.6×
The dump’s 48.4× P/E is roughly correct on an operating basis. Headline P/E of 35.2× includes the demerger gain fluke.
Financials Comparison Table: Latest Quarter vs. Year-Ago vs. Previous Quarter
Metric
Q4 FY26
Q4 FY25
Q3 FY26
Revenue
₹16,351 cr
₹15,190 cr
₹15,919 cr
YoY Growth %
+7.6%
–
–
QoQ Growth %
+2.7%
–
–
EBITDA
₹3,837 cr
₹3,618 cr
₹3,782 cr
EBITDA Margin %
23.5%
23.8%
23.8%
PAT (Operating)
₹2,711 cr
₹2,601 cr
₹2,694 cr
PAT (Reported)
₹3,002 cr*
₹2,475 cr
₹6,603 cr**
EPS (Operating)
₹11.53
₹11.07
₹11.43
*Q4 reported includes Nutritionalab divestment gain (~₹291 cr) **Q3 reported includes KWIL demerger gain (~₹4,611 cr)
The Commentary:
Revenue grew 7.6% YoY and 2.7% sequentially. The YoY pop is real—finally breaking out of 2–3% purgatory. QoQ growth looks soft (2.7%) because Q3 was already normalized post-GST transition. So the trend is up, but not parabolic.
EBITDA margin stayed flat YoY (23.5% vs. 23.8%), slight compression despite revenue leverage. This is worrying. If you’re growing faster, margin should expand. It didn’t. Why? Higher A&P spend (management said absolute A&P up ₹185–200 cr YoY), plus input cost inflation in non-feedstock items (sulphuric acid, other chemicals) hitting Home Care. So growth came at margin cost. The 23.7% guidance range is being met, but only because revenue growth absorbed input pressures.
PAT (Operating): Up 4.2% YoY (₹2,711 cr vs. ₹2,601 cr). Anemic. The miss? Lower “other income” (interest income down ~₹80 cr YoY because rates fell) and the ₹113 cr gratuity charge. Strip both, and PAT growth would be ~6–7%. Still not great for 7.6% revenue growth.
Management claims full-year FY26 operating PAT would’ve grown 4% if adjusted for gratuity. The dividend (₹41 per share) is being funded by capital returns, not earnings. This is unsustainable if earnings growth stays at 4%.
Key Takeaway: Revenue acceleration is real, but profitability lagged. Margins compressed, PAT growth underwhelmed. This isn’t the operating leverage story the headline suggests.
5. WHAT’S COOKING – NEWS, TRIGGERS, DRAMA
Ice Cream Demerger (December 2024): HUL spun off Kwality Wall’s ice cream business into KWIL and listed it on 16 Feb 2026. The ₹4,611 crore gain in Q3 (which HUL booked as demerger finalization) masked the fact that ice cream was a dead weight—capital-intensive, low-margin, exposed to seasonality. Unloading it was smart, but the way HUL did it (bundling into a separate company, flooding the market with a new listing) screams “we couldn’t sell this to anyone else.” Trading started at ₹225ish, down 30%+ from implied valuations. KWIL’s problem now.
Minimalist Acquisition (April 2024): HUL bought 90.5% of Minimalist (D2C skincare/haircare startup) in April 2025 for ~₹100 cr (est.). The bet: premiumization + DTC + younger demographic. Reality check: Q4 guidance said “strong double-digit growth,” but it’s still a rounding error in HUL’s P&L. Fair valuation gains in Q4 suggest HUL is already concerned the acquisition overpaid. Watch for impairment charges.
OZiva Full Control (February 2026): HUL owned 51%, paid ₹824 cr to take 100% in Feb 2026. OZiva is a health supplement DTC brand. ARR cited as part of ₹1,100 cr combined (with Minimalist). Again, fair valuation gains in the quarter hint that the ₹824 cr acquisition might be overpriced. CFO’s spin: “Scaled significantly over 3 years; innovation flywheel.” Reality: DTC supplement brands are competitive hellholes, and HUL’s playbook (distribution, ads, pricing power) doesn’t transfer to 22-year-olds buying protein powder on Instagram.
Nutritionalab Divestment (February 2026): HUL sold its 19.8% stake in Nutritionalab (Wellbeing Nutrition) to USV for ₹307 cr. This was meant to be a strategic health/wellness play. Instead, it became a quick exit (minority stake, no control, no synergy). CFO’s quote: “Faster, more decisive portfolio rotation.” Translation: “We made a bad bet, got out, and are using the proceeds to fund OZiva/Minimalist overpayments.”
Quick Commerce Reorganization: Management created a dedicated “quick commerce organization” with a dedicated leader reporting to the Sales Head. QC is 3% of business, growing 100% YoY (off a base of ~₹1,900 cr). It’s still negligible, but the re-org suggests desperation. Traditional channels (rural, modern trade) are cooling; QC is the only thing growing 2x. Problem: QC margins are razor-thin (platform takes 15–25%), and it’s not scalable for commodity FMCG.
Premium Capex Bet: In February, HUL approved up to ₹2,000 cr capex over two years to expand premium category manufacturing. This is the category design/deploy org talking—they want to build manufacturing for higher-margin hair care, skincare, specialty products. It’s a long-term play, but it ties up cash. With acquisitions already burning balance sheet, this adds pressure.
Macro Tailwinds Fading: HUL’s commentary acknowledged “heightened geopolitical tensions” causing “commodity and currency volatility.” Translation: crude prices spiking (bad for detergent margins), rupee weakening (bad for imported inputs). Input costs are re-inflating. This is the reverse of the tailwind that drove Q4.
5B. VALUATION – FAIR VALUE RANGE
Method 1: P/E Valuation
Industry P/E (Peer Group Average): From peer table in dump:
